The addition of standard-fluence verteporfin photodynamic therapy (PDT) delivered on the first day to a Lucentis (ranibizumab) regimen for choroidal neovascularisation (CNV) secondary to age-related macular degeneration (AMD) does not improve outcomes at 1 year of follow-up compared with Lucentis monotherapy, according to a new study. Despite...

Combination therapies generated greater visual acuity gains with fewer reinjections compared with monotherapy in a phase 2 study of patients with exudative age-related macular degeneration. In the phase 2 RADICAL (Reduced fluence Visudyne anti-VEGF-dexamethasone in combination for AMD lesions) study, mean gain in visual acuity from baseline in 3...

Combined verteporfin photodynamic therapy (PDT) and Lucentis (ranibizumab) shows promising results for the treatment of polypoidal choroidal vasculopathy (PCV). Polypoidal choroidal vasculopathy (PCV) is a condition characterized by multiple, recurrent, serosanguinous pigment epithelial detachment (PED), and neurosensory retinal detachment due...

Intravitreal injection of an anti-VEGF agent and a complement inhibitor proved safe in treating age-related macular degeneration, Dr Scott Cousins, said at the Association for Research in Vision and Ophthalmology 2010 meeting. "Drusen contain all the different complement family of molecules, not just the effectors but also the activator and...

Intravitreal Avastin (bevacizumab, IVB) combined with intravitreal triamcinolone acetonide (steroid, IVTA) may provide temporary improvement of exudative age-related macular degeneration (AMD) after unsuccessful Avastin monotherapy, according to a recent research report. No single therapy completely addresses all of the ways that neovascular...

Combined therapy using intravitreal Avastin (bevacizumab) followed by photodynamic therapy (PDT) is safe and effective in eyes with retinal angiomatous proliferation (RAP), according to a new study. Retinal angiomatous proliferation is a distinct form of neovascular age-related macular degeneration (AMD) associated with angiomatous...

The addition of photodynamic therapy (PDT) to Avastin (bevacizumab) treatment of neovascular age-related macular degeneration (AMD) does not improve the visual outcome nor decrease the number of required injections, according to a new study. Despite the success of anti-VEGF therapy in the treatment of wet AMD, there are concerns regarding the...

The ability of anti-VEGF therapy to stop fluid accumulation in the macula after neovascularization secondary to age-related macular degeneration (AMD) has been proven in clinical studies, but no clear answers are yet available on the appropriate endpoint of therapy. Despite success in treating leakage from new blood vessels, anti-VEGF therapy...

Combination therapy of intravitreal Avastin (bevacizumab, IVB) plus verteporfin photodynamic therapy (PDT) is more effective than PDT alone in the treatment of neovascular age-related macular degeneration, according to a new study. PDT with Visudyne (verteporfin) was the first available drug therapy for patients with subfoveal CNV caused by...

Intravitreal Avastin (bevacizumab) alone has similar efficacy and safety to Avastin plus photodynamic therapy (PDT) for treatment of patients with neovascular age-related macular degeneration (AMD), according to a new study. Forty-one patients with neovascular AMD (n = 31) or polypoidal choroidal vasculopathy (PCV) (n = 10) were randomized to...